Department of Pharmacy, JJN1-02, Cleveland Clinic, Cleveland, OH 44195, USA.
Cleve Clin J Med. 2010 Jan;77(1):19-27. doi: 10.3949/ccjm.77a.09084.
The US Food and Drug Administration (FDA), concerned about the incidence of acute liver failure due to acetaminophen (Tylenol) overdose, has mandated new labeling on acetaminophen packaging. It is also considering (but has not enacted) reducing the maximum daily dose from 4 g (possibly to 3,250 mg), banning acetaminophen-narcotic combination products, and changing the current maximum single dose of 1 g to prescription status, making 650 mg the highest recommended nonprescription dose. We review the epidemiology, toxicology, and management of acetaminophen overdose and steps the FDA and physicians can take to prevent it.
美国食品和药物管理局(FDA)对乙酰氨基酚(泰诺)过量导致急性肝衰竭的发生率感到担忧,已强制要求在乙酰氨基酚包装上添加新的标签。它还在考虑(但尚未颁布)降低最大日剂量,从 4 克(可能降至 3250 毫克),禁止乙酰氨基酚-麻醉品组合产品,并将当前的最大单次剂量 1 克改为处方状态,使 650 毫克成为最高推荐的非处方剂量。我们回顾了乙酰氨基酚过量的流行病学、毒理学和管理,以及 FDA 和医生可以采取的预防措施。